Reviewed by Sarim Mir, MD — Board-Certified Neurologist, Mir Neurology (Hagerstown & Cumberland, MD)
Key takeaways
- The FDA approved an updated titration (gradual ramp-up) dosing schedule for donanemab (brand name Kisunla), an Alzheimer’s treatment.
- In the TRAILBLAZER-ALZ 6 study, the modified schedule significantly lowered the rate of ARIA-E (brain swelling) while keeping the drug’s effect on amyloid.
- ARIA is a known side effect of amyloid-clearing drugs; the new schedule is about making treatment safer, not changing who qualifies.
- Donanemab is FDA-approved for early symptomatic Alzheimer’s and still requires MRI monitoring.
- This change improves safety — it is not a cure for Alzheimer’s.
What changed
The FDA approved an updated label for donanemab (Kisunla) that changes how the medicine is started. Instead of the original ramp-up, patients now follow a modified titration schedule — a different way of stepping up the dose in the first months of treatment. This update is based on results from the TRAILBLAZER-ALZ 6 study, which compared dosing approaches and found that the new schedule significantly reduced the frequency of ARIA-E (the swelling form of a side effect called ARIA) while still clearing amyloid effectively.
In plain terms: same medicine, smarter on-ramp. The goal is to keep the benefit while lowering one of the main safety risks during the early weeks of treatment.
A plain-English explainer of ARIA and amyloid
Alzheimer’s disease slowly damages the brain and is the leading cause of dementia. One feature of the disease is the buildup of a sticky protein called amyloid, which clumps into plaques between brain cells. Donanemab is an antibody — a lab-made protein — that attaches to amyloid plaques and helps the body remove them, aiming to slow the worsening of memory and thinking in early Alzheimer’s.
When the body clears amyloid this quickly, the blood vessels and tissue in the brain can react. That reaction is called ARIA, short for amyloid-related imaging abnormalities. There are two main types:
- ARIA-E (“E” for edema) is temporary swelling or fluid in the brain.
- ARIA-H (“H” for hemorrhage) is tiny spots of bleeding.
Most ARIA causes no symptoms and is found only on MRI. But sometimes it leads to headache, confusion, dizziness, nausea, or vision changes, and in rare cases it can be serious. That is why everyone on these medicines gets regular MRI scans. People who carry two copies of the APOE4 gene have a higher ARIA risk.
How it works / what’s different
The original donanemab schedule moved patients up to the full dose on a set timeline. The new titration schedule shifts how much medicine is given in the earliest infusions, smoothing out the start so the brain has more time to adjust. In TRAILBLAZER-ALZ 6, this modest change in timing meaningfully cut the rate of ARIA-E without weakening the drug’s ability to lower amyloid.
For patients and families, the takeaways are practical:
- Same goal, safer start. You still receive donanemab to clear amyloid, but with a lower chance of early brain swelling.
- Monitoring continues. MRI scans before and during treatment are still required, because ARIA can still occur.
- Eligibility is unchanged. This is a dosing update, not a change in who can take the drug.
What this means for you in Hagerstown & Cumberland
For Western Maryland families weighing an amyloid-clearing therapy, safety is often the biggest question. A dosing update that lowers the risk of brain swelling makes that conversation easier — but it does not remove the need for careful evaluation and monitoring. At Mir Neurology, Dr. Sarim Mir confirms whether a patient has early symptomatic Alzheimer’s, reviews APOE genetic risk, checks for bleeding risks, and builds the MRI monitoring schedule that keeps treatment as safe as possible.
If memory changes are affecting you or someone you love, an accurate diagnosis comes first — many causes of memory trouble are treatable and unrelated to Alzheimer’s. Explore our Alzheimer’s disease care and memory & cognitive evaluations.
Call (301) 797-7600 to request an appointment, or request an appointment online.
Frequently asked questions
Does the new dosing schedule mean donanemab is now safe for everyone? No. The updated titration lowers the chance of ARIA-E, but ARIA can still happen, and the drug isn’t right for everyone. Your neurologist will review your MRI, genetic risk, and bleeding history before recommending it.
Do I still need MRI scans on the new schedule? Yes. Regular MRI monitoring before and during treatment is still required to catch ARIA early, even though the new schedule reduces the risk of brain swelling.
Will the new schedule make the medicine less effective? The TRAILBLAZER-ALZ 6 study found the modified titration kept donanemab’s effect on clearing amyloid while lowering ARIA-E. The aim was to improve safety without sacrificing benefit.
This article is for general education and is not a substitute for personalized medical advice from your own physician.
Sources: NeurologyLive — FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk
Need to talk to a neurologist about this?
Mir Neurology offers same-week appointments in Hagerstown & Cumberland, MD. No referral needed for most plans.
